Mainz Biomed (MYNZ)

• Market cap: $14.8M
• 1 day: 40.04%
• 5 days: 24.86%
• 1 month: -25.45%
• 3 months: -31.28%
• 6 months: -70.18%
• Year to date: -85.73%
• 1 year: -85.73%
• 5 years: -98.33%
• 10 years: -98.33%

About: Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

Employees: 71

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

22% more funds holding

Funds holding: 9 [Q2] → 11 (+2) [Q3]

9% more capital invested

Capital invested by funds: $41.5K [Q2] → $45.3K (+$3.75K) [Q3]

0.36% more ownership

Funds ownership: 0.47% [Q2] → 0.83% (+0.36%) [Q3]